Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (NASDAQ: BCRX) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the day. That fall was far steeper than the 0.5% slip of the benchmark S&P 500 (SNPINDEX: ^GSPC).

A mixed final quarter of 2024

For the quarter, BioCryst managed to increase its revenue by 41% to $131.5 million. The company also narrowed its generally accepted accounting principles (GAAP) net loss; this came in at $26.8 million ($0.13 per share) against the $61.7 million deficit it posted in the same quarter the previous year.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

The biotech beat the consensus analyst estimate for revenue, which was slightly over $127 million. However, it missed quite widely for net loss, as those pundits were collectively anticipating only a $0.07 per share shortfall.

As in previous quarters, BioCryst's results were driven largely by its one commercialized product: hereditary angioedema treatment, Orladeyo. The drug saw a 37% improvement in sales to slightly over $124 million. BioCryst said in its earnings release that it's aiming to submit a New Drug Application to the Food and Drug Administration (FDA) to get the medicine approved for children aged 2 to 11.

Guidance raised, thanks to Orladeyo

Management also raised guidance for both Orladeyo sales and overall revenue for all of 2025. For the former, it now believes the drug will bring in $535 million to $550 million; before, it was modeling $515 million to $535 million. This will, of course, boost overall revenue, which is now expected to come in at $560 million to $575 million (old projection: $540 million to $560 million).

BioCryst is something of a one-trick pony at the moment, but that's not unusual for relatively young biotechs. I think it's doing well with Orladeyo, and it has other drugs in its pipeline, so I'd probably be more bullish on its prospects than investors were on Monday.

Should you invest $1,000 in BioCryst Pharmaceuticals right now?

Before you buy stock in BioCryst Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BioCryst Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $823,858!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

Learn more »

*Stock Advisor returns as of February 24, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.